Validation of the Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) Model

被引:41
作者
Binenbaum, Gil [1 ,2 ]
Ying, Gui-shuang [2 ]
Tomlinson, Lauren A. [1 ]
机构
[1] Childrens Hosp Philadelphia, Ophthalmol 9 MAIN,3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[2] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
POSTNATAL WEIGHT-GAIN; SCREENING ALGORITHM WINROP; PRETERM INFANTS; PROGNOSTIC RESEARCH; BIRTH-WEIGHT; COLORADO-RETINOPATHY; PREDICTION; GROWTH; AGE; PROGRESSION;
D O I
10.1001/jamaophthalmol.2017.2295
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
IMPORTANCE The Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model uses birth weight (BW), gestational age at birth (GA), and weight gain rate to predict the risk of severe retinopathy of prematurity (ROP). In a model development study, it predicted all infants requiring treatment, while greatly reducing the number of examinations compared with current screening guidelines. OBJECTIVE To validate the CHOP ROP model in a multicenter cohort that is large enough to obtain a precise estimate of the model's sensitivity for treatment-requiring ROP. DESIGN, SETTING, AND PARTICIPANTS This investigation was a secondary analysis of data from the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. The setting was 30 hospitals in the United States and Canada between January 1, 2006, and June 30, 2012. The dates of analysis were September 28 to October 5, 2015. Participants were premature infants at risk for ROP with a known ROP outcome. MAIN OUTCOMES AND MEASURES Sensitivity for Early Treatment of Retinopathy of Prematurity type 1 ROP and potential reduction in the number of infants requiring examinations. In the primary analysis, the CHOP ROP model was applied weekly to predict the risk of ROP. If the risk was above a cut-point level (high risk), examinations were indicated, while low-risk infants received no examinations. In a secondary analysis, low-risk infants received fewer examinations rather than no examinations. RESULTS Participants included 7483 premature infants at risk for ROP with a known ROP outcome. Their median BW was 1070 g (range, 310-3000 g), and their median GA was 28 weeks (range, 22-35 weeks). Among them, 3575 (47.8%) were female, and their race/ethnicity was 3615 white (48.3%), 2310 black (30.9%), 233 Asian (3.1%), 93 Pacific Islander (1.2%), and 40 American Indian/Alaskan native (0.5%). The original CHOP ROP model correctly predicted 452 of 459 infants who developed type 1 ROP (sensitivity, 98.5%; 95% CI, 96.9%-99.3%), reducing the number of infants requiring examinations by 34.3% if only high-risk infants received examinations. Lowering the cut point to capture all type 1 ROP cases (sensitivity, 100%; 95% CI, 99.2%-100%) resulted in only 6.8% of infants not requiring examinations. However, if low-risk infants were examined at 37 weeks' postmenstrual age and followed up only if ROP was present at that examination, all type 1 ROP cases would be captured, and the number of examinations performed among infants with GA exceeding 27 weeks would be reduced by 28.4%. CONCLUSION AND RELEVANCE The CHOP ROP model demonstrated high but not 100% sensitivity and may be better used to reduce examination frequency. The model might be used reliably to guide a modified ROP screening schedule and decrease the number of examinations performed.
引用
收藏
页码:871 / 877
页数:7
相关论文
共 37 条
  • [21] SERUM INSULIN-LIKE GROWTH-FACTORS AND INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS IN THE HUMAN FETUS - RELATIONSHIPS WITH GROWTH IN NORMAL SUBJECTS AND IN SUBJECTS WITH INTRAUTERINE GROWTH-RETARDATION
    LASSARRE, C
    HARDOUIN, S
    DAFFOS, F
    FORESTIER, F
    FRANKENNE, F
    BINOUX, M
    [J]. PEDIATRIC RESEARCH, 1991, 29 (03) : 219 - 225
  • [22] Evidence for changing guidelines for routine screening for retinopathy of prematurity
    Lee, SK
    Normand, C
    McMillan, D
    Ohlsson, A
    Vincer, M
    Lyons, C
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2001, 155 (03): : 387 - 395
  • [23] Lentner C, 1982, GEIGY SCI TABLES, V2
  • [24] Validation of a New Retinopathy of Prematurity Screening Method Monitoring Longitudinal Postnatal Weight and Insulinlike Growth Factor I
    Loqvist, Chatarina
    Hansen-Pupp, Ingrid
    Andersson, Eva
    Holm, Kristina
    Smith, Lois E. H.
    Ley, David
    Hellstrom, Ann
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (05) : 622 - 627
  • [25] Efficacy of Intravitreal Bevacizumab for Stage 3+Retinopathy of Prematurity.
    Mintz-Hittner, Helen A.
    Kennedy, Kathleen A.
    Chuang, Alice Z.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (07) : 603 - 615
  • [26] Prognosis and prognostic research: application and impact of prognostic models in clinical practice
    Moons, Karel G. M.
    Altman, Douglas G.
    Vergouwe, Yvonne
    Royston, Patrick
    [J]. BRITISH MEDICAL JOURNAL, 2009, 338 : 1487 - 1490
  • [27] Prognosis and prognostic research: what, why, and how?
    Moons, Karel G. M.
    Royston, Patrick
    Vergouwe, Yvonne
    Grobbee, Diederick E.
    Altman, Douglas G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1317 - 1320
  • [28] PALMER EA, 1994, ARCH OPHTHALMOL-CHIC, V112, P903
  • [29] PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628
  • [30] Piermarocchi S, 2016, ACTA OPHTHALMOL